Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with …
この記事を読む
記事一覧
この記事を読む
進行非小細胞肺癌の20年間での予後改善
Evolving treatments and prognosis in Stage IV non-small cell lung cancer: 20 years of progress of novel therapies. Satoh…
この記事を読む
非劣勢試験は見直すべきか？
The tyranny of non-inferiority trials. Tannock IF et al.Lancet Oncol.2024 Oct;25(10):e520-e525.PMID:39362263. Abs of abs…
この記事を読む
KRAS変異部位により背景、免疫療法への反応が異なる
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations. Shahnam A et al…
この記事を読む
末梢小型肺癌は細かく考える
Risk Factors for Locoregional Relapse After Segmentectomy:Supplementary Analysis of the JCOG0802/WJOG4607L Trial. Nakaga…
この記事を読む
オシメルチニブ心毒性のリスク因子
The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population. Bak M et al.J Thorac Oncol.…
この記事を読む
PD後の免疫療法継続の利益はmGPSで分かる？
The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression. Saal J …
この記事を読む
「ドライバー変異なし」でもCGP検査で25%に標的遺伝子変異が見つかる
Clinical utility of comprehensive genomic profiling in non-small cell lung cancer: An analysis of a nation-wide database…
この記事を読む
大規模臨床試験データでのLIPIの有用性の検証
Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc …
この記事を読む
抗PD-1抗体無効後のPD-L1抗体：アテゾリズマブ投与
Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Dire…